Dealing by Person Closely Associated
November 01, 2016 11:30 ET
|
AstraZeneca PLC
1 November 2016 15:30
Transaction by Person Closely Associated with a Person Discharging Managerial
Responsibilities
Disclosure under Articles 19(3) and 19(6) of the EU Market Abuse Regulation
On...
AZ completes US Aralez agreement for Toprol-XL
October 31, 2016 10:19 ET
|
AstraZeneca PLC
31 October 2016 13:45
ASTRAZENECA COMPLETES AGREEMENT WITH ARALEZ
FOR BETA-BLOCKER MEDICINE TOPROL-XL IN THE US
AstraZeneca today announced the completion of...
AstraZeneca Head and Neck Cancer Trials
October 27, 2016 12:02 ET
|
AstraZeneca PLC
27 October 2016 16:50
ASTRAZENECA HEAD AND NECK CANCER TRIALS
Following the recent update on clinicaltrials.gov, AstraZeneca confirms that the
US FDA has placed a partial clinical hold on the...
Positive results in AstraZeneca Lynparza trial
October 26, 2016 02:00 ET
|
AstraZeneca PLC
This announcement contains inside information
26 October 2016 07:00
LYNPARZA PHASE III SOLO-2 TRIAL SHOWS SIGNIFICANT PROGRESSION-FREE SURVIVAL
BENEFIT
Trial studied Lynparza as maintenance...
FDA ACCEPTS FOR REVIEW NEW DRUG APPLICATION FOR SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) FOR THE TREATMENT OF HYPERKALAEMIA
October 18, 2016 02:00 ET
|
AstraZeneca PLC
18 October 2016 [07:00]
AstraZeneca today announced that the US Food and Drug Administration (FDA) has
accepted a complete re-submission of a New Drug Application (NDA) for sodium
zirconium...
AZ agreement with Aralez for Toprol-XL in US
October 04, 2016 02:05 ET
|
AstraZeneca PLC
This announcement contains inside information
4 October 2016 07:05
ASTRAZENECA ENTERS AGREEMENT WITH ARALEZ
FOR BETA-BLOCKER MEDICINE TOPROL-XL IN THE US
AstraZeneca today announced that it has...
AstraZeneca reports top-line EUCLID results in PAD
October 04, 2016 02:00 ET
|
AstraZeneca PLC
This announcement contains inside information
04 October 2016 07:00
ASTRAZENECA REPORTS TOP-LINE RESULTS FROM THE BRILINTA EUCLID TRIAL IN PATIENTS
WITH PERIPHERAL ARTERY DISEASE
Brilinta did not...
Total Voting Rights
October 03, 2016 10:00 ET
|
AstraZeneca PLC
3 October 2016 15:00
Transparency Directive
Voting Rights and Capital
The following notification is made in accordance with the UK Financial Conduct
Authority's Disclosure and Transparency Rule...
ASTRAZENECA PLC ANNOUNCES MEDIMMUNE OUT-LICENSES POTENTIAL MEDICINE FOR INFLAMMATORY DISEASES TO ALLERGAN
October 03, 2016 02:00 ET
|
AstraZeneca PLC
This announcement contains inside information
03 October 2016 07:00
AstraZeneca today announced that MedImmune, its global biologics research and
development arm, has entered into a licensing...
CHANGE TO ASTRAZENECA BOARD OF DIRECTORS
September 28, 2016 02:00 ET
|
AstraZeneca PLC
28 September 2016 07:00
CHANGE TO ASTRAZENECA BOARD OF DIRECTORS
AstraZeneca today announced that Dr Cornelia (Cori) Bargmann, a Non-Executive
Director, will step down from the Board of AstraZeneca...